#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	17856	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2092	847.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1460	1460	C	1061	C	987	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32652	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3744	870.0	0	.	n	.	0	T695C	SNP	695	695	T	1024	1024	C	982	C,T	913,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32652	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3744	870.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1666	1666	A	1061	A	1001	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32652	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3744	870.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2300	2300	C	1042	C,A	977,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32652	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3744	870.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2374	2374	A	1002	A,G	947,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32652	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3744	870.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	2926	2926	C	1007	C	947	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2160	folP	852	852	100.0	folP.l15.c4.ctg.1	1382	154.8	1	SNP	p	R228S	1	.	.	682	684	AGC	915	917	AGC	243;248;249	A;G,A;C	227;227,1;233	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5176	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3327	154.9	1	SNP	p	S91F	0	.	.	271	273	TCC	546	548	TCC	199;202;206	T,G;C;C	182,1;186;190	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5176	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3327	154.9	1	SNP	p	D95G	0	.	.	283	285	GAC	558	560	GAC	196;195;192	G,T;A;C	180,1;181;182	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5176	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3327	154.9	1	SNP	p	D95N	0	.	.	283	285	GAC	558	560	GAC	196;195;192	G,T;A;C	180,1;181;182	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1776	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1316	134.3	0	.	p	.	0	A39T	NONSYN	115	117	GCC	397	399	ACC	226;223;221	A;C;C	209;210;208	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1776	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1316	134.3	0	.	p	.	0	R44H	NONSYN	130	132	CGC	412	414	CAC	216;216;213	C;A;C	202;197;199	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1776	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1316	134.3	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	595	597	CAC	217;218;215	C;A;C	208;209;203	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1776	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1316	134.3	1	SNP	p	G45D	0	.	.	133	135	GGC	415	417	GGC	212;214;214	G;G;C	196;199;199	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1008	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	1086	92.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5724	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3006	189.7	1	SNP	p	D86N	0	.	.	256	258	GAC	661	663	GAC	218;219;219	G;A;C	205;204;205	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5724	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3006	189.7	1	SNP	p	S87I	0	.	.	259	261	AGT	664	666	AGT	220;219;223	A;G;T	205;206;206	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5724	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3006	189.7	1	SNP	p	S87W	0	.	.	259	261	AGT	664	666	AGT	220;219;223	A;G;T	205;206;206	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5724	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3006	189.7	1	SNP	p	S87R	0	.	.	259	261	AGT	664	666	AGT	220;219;223	A;G;T	205;206;206	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5724	parC	2304	2304	100.0	parC.l15.c30.ctg.1	3006	189.7	1	SNP	p	S88P	0	.	.	262	264	TCC	667	669	TCC	219;221;223	T;C;C	209;208;212	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4630	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2573	179.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1564	1566	GGC	212;211;212	G;G;C	199;196;198	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4558	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2364	191.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1231	1233	GCA	260;254;255	G;C;A	241;238;240	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4558	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2364	191.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1234	1236	ATC	256;255;255	A;T;C	238;240;240	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4558	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2364	191.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1246	1248	GTG	243;244;246	G;T;G	233;232;236	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4558	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2364	191.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1246	1248	GTG	243;244;246	G;T;G	233;232;236	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4558	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2364	191.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1750	1752	ACC	238;237;238	A;C;C,A	219;224;223,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4558	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2364	191.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1804	1806	GCG	248;247;248	G;C;G	220;194;204	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4558	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2364	191.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1804	1806	GCG	248;247;248	G;C;G	220;194;204	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4558	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2364	191.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1927	1929	GGC	206;201;199	G;G;C	196;193;190	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4558	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2364	191.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1936	1938	GGC	195;194;193	G;G;C	182;179;178	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4558	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2364	191.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1954	1956	CCG	158;164;166	C,G;C,A;G	127,3;129,1;133	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6390	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3149	202.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2434	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1955	124.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	562	562	C	187	C	171	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	371	38.9	0	.	p	.	0	S271T	NONSYN	811	813	TCG	123	125	ACT	82;82;82	A;C;T	76;76;76	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	371	38.9	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	129	131	GAT	73;71;69	G;A;T	69;68;67	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	371	38.9	0	.	p	.	0	D276N	NONSYN	826	828	GAT	138	140	AAC	71;72;72	A;A;C	67;67;68	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	371	38.9	0	.	p	.	0	N277H	NONSYN	829	831	AAC	141	143	CAC	72;72;72	C;A;C	67;67;68	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	371	38.9	0	.	p	.	0	R307E	NONSYN	919	921	AGA	231	233	GAA	26;26;27	G;A;A	26;26;27	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	371	38.9	0	.	p	.	0	T311A	NONSYN	931	933	ACA	243	245	GCA	26;26;26	G;C;A	26;26;26	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	371	38.9	0	.	p	.	0	E312D	NONSYN	934	936	GAA	246	248	GAC	24;24;24	G;A;C	23;24;24	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	371	38.9	0	.	p	.	0	F314I	NONSYN	940	942	TTC	252	254	ATC	24;24;24	A;T;C	24;24;24	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	371	38.9	0	.	p	.	0	A316S	NONSYN	946	948	GCG	258	260	TCG	23;23;23	T;C;G	23;23;23	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	371	38.9	0	.	p	.	0	V318A	NONSYN	952	954	GTC	264	266	GCC	23;22;22	G;C;C	23;22;22	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	371	38.9	0	.	p	.	0	G319S	NONSYN	955	957	GGC	267	269	AGC	22;22;22	A;G;C	22;22;22	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	371	38.9	0	.	p	.	0	G320A	NONSYN	958	960	GGT	270	272	GCC	21;21;22	G;C;C	21;21;22	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	271	91.51	porB1a.l6.c30.ctg.2	371	38.9	0	.	p	.	0	G322V	NONSYN	964	966	GGT	276	278	GTT	22;22;22	G;T;T	22;22;22	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	112	91.96	porB1a.l6.c30.ctg.3	342	59.1	0	.	p	.	0	M18T	NONSYN	52	54	ATG	203	205	ACG	106;106;105	A;C;G	97;97;96	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	112	91.96	porB1a.l6.c30.ctg.3	342	59.1	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	245	247	CAA	54;49;46	C;A;A	52;46;44	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	434	porB1a	984	112	91.96	porB1a.l6.c30.ctg.3	342	59.1	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	251	253	TAC	32;30;28	T;A;C	31;28;28	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3638	porB1b	1047	1047	98.09	porB1b.l15.c17.ctg.1	1357	263.0	0	.	p	.	0	A26T	NONSYN	76	78	GCC	243	245	ACC	289;285;284	A;C;C,G	266;263;264,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3638	porB1b	1047	1047	98.09	porB1b.l15.c17.ctg.1	1357	263.0	0	.	p	.	0	G120N	NONSYN	358	360	GGC	525	527	AAT	268;268;270	A;A;T	257;257;258	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3638	porB1b	1047	1047	98.09	porB1b.l15.c17.ctg.1	1357	263.0	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	726	728	CGA	302;302;304	C,T;G;A	284,1;285;288	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3638	porB1b	1047	1047	98.09	porB1b.l15.c17.ctg.1	1357	263.0	0	.	p	.	0	S189G	NONSYN	565	567	AGC	732	734	GGC	312;311;311	G;G,T;C	294;293,1;293	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3638	porB1b	1047	1047	98.09	porB1b.l15.c17.ctg.1	1357	263.0	0	.	p	.	0	E212D	NONSYN	634	636	GAA	801	803	GAT	278;278;277	G;A;T	263;263;263	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3638	porB1b	1047	1047	98.09	porB1b.l15.c17.ctg.1	1357	263.0	0	.	p	.	0	H213N	NONSYN	637	639	CAT	804	806	AAT	278;276;278	A,G;A;T	264,1;265;265	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3638	porB1b	1047	1047	98.09	porB1b.l15.c17.ctg.1	1357	263.0	0	.	p	.	0	V215F	NONSYN	643	645	GTT	810	812	TTT	272;271;270	T;T;T	259;259;258	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3638	porB1b	1047	1047	98.09	porB1b.l15.c17.ctg.1	1357	263.0	0	.	p	.	0	I218V	NONSYN	652	654	ATC	819	821	GTC	275;275;276	G;T;C	261;258;261	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3638	porB1b	1047	1047	98.09	porB1b.l15.c17.ctg.1	1357	263.0	0	.	p	.	0	A256T	NONSYN	766	768	GCA	933	935	ACA	323;323;324	A;C;A	307;306;307	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3638	porB1b	1047	1047	98.09	porB1b.l15.c17.ctg.1	1357	263.0	0	.	p	.	0	R257W	NONSYN	769	771	AGG	936	938	TGG	320;321;318	T;G,T;G	302;302,1;297	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3638	porB1b	1047	1047	98.09	porB1b.l15.c17.ctg.1	1357	263.0	0	.	p	.	0	S295D	NONSYN	883	885	AGT	1050	1052	GAT	306;308;304	G;A;T	285;284;283	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3638	porB1b	1047	1047	98.09	porB1b.l15.c17.ctg.1	1357	263.0	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1056	1058	AAC	305;306;306	A;A;C	283;285;283	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3638	porB1b	1047	1047	98.09	porB1b.l15.c17.ctg.1	1357	263.0	1	SNP	p	A121D	1	.	.	361	363	GAC	528	530	GAC	268;265;269	G;A;C	256;256;259	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3638	porB1b	1047	1047	98.09	porB1b.l15.c17.ctg.1	1357	263.0	1	SNP	p	D121N	0	.	.	361	363	GAC	528	530	GAC	268;265;269	G;A;C	256;256;259	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	13332	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	4872	272.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2020	2022	CAT	273;271;270	C;A;T	257;256;252	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1404	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	962	144.6	1	SNP	p	V57M	1	.	.	169	171	ATG	497	499	ATG	300;299;296	A;T;G	290;290;286	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
